Table 1.

Functional and pathway enrichment analyses of the DEGs in trastuzumab-resistant gastric cancer.

	Category	Description	Count	P value
GO function	BP	Type I interferon signaling pathway	13	1.04E − 09
	BP	Negative regulation of viral genome replication	10	2.46E − 08
	BP	Cell proliferation	23	5.99E − 07
	BP	Positive regulation of apoptotic process	18	2.51E − 05
	BP	Extracellular matrix organization	13	1.92E − 04
	CC	Extracellular exosome	90	1.28E − 09
	CC	Intermediate filament	11	2.26E − 05
	CC	Cytoplasm	122	3.98E − 05
	CC	Proteinaceous extracellular matrix	16	5.65E − 05
	CC	Basolateral plasma membrane	13	5.98E − 05
	MF	Structural molecule activity	17	8.93E − 06
	MF	Calcium ion binding	27	4.52E − 04
	MF	Protein homodimerization activity	26	1.31E − 03
	MF	2′-5′-oligoadenylate synthetase activity	3	1.83E − 03
	MF	Fibronectin binding	4	1.06E − 02
KEGG pathway
	hsa05200	Pathways in cancer	18	5.47E − 04
	hsa04550	Signaling pathways regulating pluripotency of stem cells	8	1.22E − 02
	hsa05166	HTLV-I infection	11	1.56E − 02
	hsa04512	ECM-receptor interaction	6	1.91E − 02
	hsa05230	Central carbon metabolism in cancer	5	2.68E − 02

Note: top five terms were selected according to P value. Abbreviation: DEGs: differentially expressed genes; GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function; HTLV-I: human T lymphocyte virus-I; ECM: extracellular matrix.